UBE2F-SCLY

Across TCGA pan-cancer cohorts, UBE2F-SCLY RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of UBE2F-SCLY’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where UBE2F-SCLY RNA is more highly expressed in tumor relative to normal tissue. In most cancer types UBE2F-SCLY is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

LIHC, THCA, and HNSC are the cancer types where UBE2F-SCLY tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in UBE2F-SCLY RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	II,III,IV	+0.032	<.001	8	view →
THCA	All	All	−0.063	<.001	7	view →
HNSC	All	II,III,IV	+0.030	<.001	7	view →
BRCA	All	II,III,IV	+0.036	.005	4	view →
KICH	Female	II,III,IV	−0.058	.001	3	view →
CHOL	All	All	+0.100	.008	2	view →
PAAD	Female	All	−0.069	.047	2	view →
ESCA	Male	All	−0.068	.028	2	view →
BLCA	Male	All	+0.054	.034	2	view →
LUAD	Male	III,IV	+0.094	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

UBE2F-SCLY–LIHC

Open the LIHC breakdown →